HLS Therapeutics (TSE:HLS) Hits New 12-Month Low – Should You Sell?

HLS Therapeutics Inc. (TSE:HLS) hit a new 52-week low on Monday . The stock traded as low as C$4.20 and last traded at C$4.24, with a volume of 21422 shares traded. The stock had previously closed at C$4.36.

HLS Therapeutics Price Performance

The company has a 50-day moving average price of C$4.55 and a two-hundred day moving average price of C$4.59. The company has a debt-to-equity ratio of 75.00, a current ratio of 1.00 and a quick ratio of 1.01. The company has a market cap of C$137.30 million, a PE ratio of -13.72 and a beta of -0.02.

HLS Therapeutics (TSE:HLS) last issued its earnings results on Friday, May 15th. The company reported C($0.10) earnings per share for the quarter. HLS Therapeutics had a negative return on equity of 16.54% and a negative net margin of 18.42%.The company had revenue of C$17.88 million during the quarter. Sell-side analysts expect that HLS Therapeutics Inc. will post -0.12 earnings per share for the current fiscal year.

About HLS Therapeutics

HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company is focused on treatment products for the central nervous system (CNS), and cardiovascular specialties. The company products include Clozaril, Absorica, Vascepa, CSAN Pronto, Trinomia and Perseris. The company earns revenue in the form of product sales and royalties, out of which product sales contribute to the majority of the revenue.